Skip to main content

ADVERTISEMENT

Yiqiong Xie, PhD, MPH

From the Field
05/19/2022
Dr Wallace and colleagues analyzed second-line poly(ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy in a real-world setting to understand how it is being utilized and the resultant impact on patients’ disease course.
Dr Wallace and colleagues analyzed second-line poly(ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy in a real-world setting to understand how it is being utilized and the resultant impact on patients’ disease course.
Dr Wallace and colleagues...
05/19/2022
Journal of Clinical Pathways